Jane Street Group LLC Sells 36,440 Shares of AVITA Medical, Inc. (NASDAQ:RCEL)

Jane Street Group LLC lessened its holdings in AVITA Medical, Inc. (NASDAQ:RCEL) by 40.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 52,955 shares of the company’s stock after selling 36,440 shares during the quarter. Jane Street Group LLC owned 0.20% of AVITA Medical worth $678,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of RCEL. JPMorgan Chase & Co. boosted its position in shares of AVITA Medical by 38.5% in the third quarter. JPMorgan Chase & Co. now owns 32,344 shares of the company’s stock valued at $347,000 after acquiring an additional 8,985 shares during the period. SG Americas Securities LLC bought a new stake in shares of AVITA Medical in the fourth quarter valued at about $190,000. AlphaQuest LLC boosted its position in shares of AVITA Medical by 24.7% in the fourth quarter. AlphaQuest LLC now owns 9,378 shares of the company’s stock valued at $120,000 after acquiring an additional 1,858 shares during the period. Essex Investment Management Co. LLC boosted its position in shares of AVITA Medical by 13.0% in the fourth quarter. Essex Investment Management Co. LLC now owns 261,171 shares of the company’s stock valued at $3,343,000 after acquiring an additional 30,077 shares during the period. Finally, Intech Investment Management LLC bought a new stake in shares of AVITA Medical in the fourth quarter valued at about $135,000. Institutional investors own 27.66% of the company’s stock.

AVITA Medical Trading Down 1.9%

Shares of AVITA Medical stock opened at $6.28 on Monday. The company has a quick ratio of 2.47, a current ratio of 2.83 and a debt-to-equity ratio of 9.39. AVITA Medical, Inc. has a 12-month low of $6.17 and a 12-month high of $14.16. The company has a market capitalization of $166.01 million, a price-to-earnings ratio of -2.63 and a beta of 1.74. The firm’s 50-day moving average price is $8.47 and its two-hundred day moving average price is $9.98.

AVITA Medical (NASDAQ:RCEL) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.14). The firm had revenue of $18.51 million for the quarter, compared to analyst estimates of $33.15 million. AVITA Medical had a negative return on equity of 337.91% and a negative net margin of 96.26%. On average, analysts forecast that AVITA Medical, Inc. will post -0.95 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, D. Boral Capital reissued a “buy” rating and issued a $22.00 target price on shares of AVITA Medical in a research report on Thursday, April 10th.

AVITA Medical Company Profile

AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.